The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised




About Vivacta

Vivacta is an in vitro diagnostic company. The company's technology aims to enable rapid, reliable and highly sensitive tests to be performed quantitatively at the Point-of-Care. Vivacta is developing a diagnostic system that is portable and precise with sensitivity comparable to lab platforms. Through relationships with Diagnostic Partners existing and newly developed laboratory-based immunoassay diagnostic tests will be transferred onto the company's platform providing a cost effective Point-of-Care solution for the partner to take to market.

Vivacta Headquarter Location

100 Guillat Avenue Kent Science Park

Sittingbourne, ME9 8GU,

United Kingdom

(+440) 179-541-9400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vivacta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vivacta is included in 1 Expert Collection, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Vivacta Patents

Vivacta has filed 13 patents.

patents chart

Application Date

Grant Date


Related Topics




Analytical chemistry, Spectroscopy, Electromagnetic radiation, Sensors, Electrical signal connectors


Application Date


Grant Date



Related Topics

Analytical chemistry, Spectroscopy, Electromagnetic radiation, Sensors, Electrical signal connectors



Latest Vivacta News

PE HUB » Vivacta Raises $12 Million

Feb 18, 2015

Friends (1) November 28, 2007    3 Views    0 Comments Vivacta, a UK-based developer of a point-of-care immunoassay system, has raised $12 million in Series B funding. AGF Private Equity and HBM BioVentures co-led the round, and were joined by return backers Spark Ventures and Viking. Get more info. PRESS RELEASE Vivacta announced today that it had raised $12 million from a successful Series B financing round. This will be used to drive forward the commercialisation and launch of its first, highly sensitive Point of Care (PoC) immunoassay system, based on its patented piezofilm sensor technology. Commenting on the deal, Neil Butler, CEO, said, “We were pleased to have the deal co-led by two very strong European Venture Capital firms, AGF Private Equity and HBM BioVentures. Our existing investors, Spark Ventures and Viking, both chose to follow on which is a very strong endorsement of Vivacta's technology platform and our approach to its commercialisation”. AGF Private Equity and HBM BioVentures will be further strengthening the Vivacta Board through the appointment of two well-known diagnostic industry leaders – Gerry Moeller and Gerard Vaillant. Gerry was previously Chief Executive of the Boehringer Mannheim group and after its acquisition joined the management board of Roche. Gerard Vaillant chaired the diagnostics division of J&J, and acted as CEO and President of Ortho Clinical and Lifescan. Neil Butler believes that, “With our existing Chairman, Rolf Classon, and Director, Werner Schaefer, these new appointments give us a Board with more combined industry know how than probably any other privately held  diagnostics company.” Vivacta is currently finalising the reader and cartridge for its rapid, highly sensitive, piezo film-based immunoassay system. It intends to begin clinical evaluation of its first PoC application, TSH, in 2008. In-line with its commercialisation plans, Vivacta is in the process of doubling the size of its facility in the Kent Science Park. This will allow the company to add a pilot manufacturing line for its disposable cartridge. Vivacta is already in discussion with a number of potential licensees that are interested in the opportunity to commercially exploit its unique piezofilm technology. About AGF Private Equity

  • Where is Vivacta's headquarters?

    Vivacta's headquarters is located at 100 Guillat Avenue, Sittingbourne.

  • What is Vivacta's latest funding round?

    Vivacta's latest funding round is Acquired.

  • How much did Vivacta raise?

    Vivacta raised a total of $22.7M.

  • Who are the investors of Vivacta?

    Investors of Vivacta include Novartis, HBM Healthcare Investments, AGF Private Equity, Spark Ventures, Viking Venture and 3 more.

  • Who are Vivacta's competitors?

    Competitors of Vivacta include Advanced Cell Diagnostics, Crescendo Bioscience, HandyLab, NIR Diagnostics, QuadraSpec and 13 more.

You May Also Like

LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

Modules for Novel Diagnostics

MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.


Quadraspec is changing the face of diagnostic medicine. Quadraspec's patented SDI label-free detection technology aims to permit the rapid analysis of up to 100 unique tests on up to 1,000 unique patients per hour. Quadraspec's , multiplex-capable diagnostics platform aims to allow high throughput, label-free, highly sensitive bioassays, and diagnostics.

Celerus Diagnostics

Celerus Diagnostics is aiming to enhance the diagnostic capabilities of the pathology laboratory. Celerus' Rapid IHC technology aims to provide the capability to decentralize testing, and move results closer to the patient for real time decision making.


Knoesis seeks to develop bio-analytical hardware and reagents enabling cost-effective clinical diagnostics. The vision of the company is to allow everyone affordable access to rapid and specific diagnostic healthcare knowledge. Knoesis' first application is an immunosensor for the detection of latent tuberculosis infection.

Hx Diagnostics

Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.